A multi-data set comparison of the vertical structure of temperature variability and change over the Arctic during the past 100years

We compare the daily, interannual, and decadal variability and trends in the thermal structure of the Arctic troposphere using eight observation-based, vertically resolved data sets, four of which have data prior to 1948. Comparisons on the daily scale between historical reanalysis data and historical upper-air observations were performed for Svalbard for the cold winters 1911/1912 and 1988/1989, the warm winters 1944/1945 and 2005/2006, and the International Geophysical Year 1957/1958. Excellent agreement is found at mid-tropospheric levels. Near the ground and at the tropopause level, however, systematic differences are identified. On the interannual time scale, the correlations between all data sets are high, but there are systematic biases in terms of absolute values as well as discrepancies in the magnitude of the variability. The causes of these differences are discussed. While none of the data sets individually may be suitable for trend analysis, consistent features can be identified from analyzing all data sets together. To illustrate this, we examine trends and 20-year averages for those regions and seasons that exhibit large sea-ice changes and have enough data for comparison. In the summertime Pacific Arctic and the autumn eastern Canadian Arctic, the lower tropospheric temperature anomalies for the recent two decades are higher than in any previous 20-year period. In contrast, mid-tropospheric temperatures of the European Arctic in the wintertime of the 1920s and 1930s may have reached values as high as those of the late 20th and early 21st centurie

On the problem of calculation of correlation functions in the six-vertex model with domain wall boundary conditions

The problem of calculation of correlation functions in the six-vertex model with domain wall boundary conditions is addressed by considering a particular nonlocal correlation function, called row configuration probability. This correlation function can be used as building block for computing various (both local and nonlocal) correlation functions in the model. The row configuration probability is calculated using the quantum inverse scattering method; the final result is given in terms of a multiple integral. The connection with the emptiness formation probability, another nonlocal correlation function which was computed elsewhere using similar methods, is also discussed.Comment: 15 pages, 2 figure

Detection of two dissimilar chronic wasting disease isolates in two captive Rocky Mountain elk (\u3ci\u3eCervus canadensis\u3c/i\u3e) herds: Two distinctive chronic wasting disease isolates identified in captive elk

Chronic wasting disease (CWD) continues to spread in both wild and captive cervid herds in North America and has now been identified in wild reindeer and moose in Norway, Finland and Sweden. There is limited knowledge about the variety and characteristics of isolates or strains of CWD that exist in the landscape and their implications on wild and captive cervid herds. In this study, we evaluated brain samples from two captive elk herds that had differing prevalence, history and timelines of CWD incidence. Site 1 had a 16-year history of CWD with a consistently low prevalence between 5% and 10%. Twelve of fourteen naïve animals placed on the site remained CWD negative after 5 years of residence. Site 2 herd had a nearly 40-year known history of CWD with long-term environmental accrual of prion leading to nearly 100% of naïve animals developing clinical CWD within two to 12 years. Obex samples of several elk from each site were compared for CWD prion strain deposition, genotype in prion protein gene codon 132, and conformational stability of CWD prions. CWD prions in the obex from site 2 had a lower conformational stability than those from site 1, which was independent of prnp genotype at codon 132. These findings suggest the existence of different CWD isolates between the two sites and suggest potential differential disease attack rates for different CWD strains

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

This study forms part of the first complete characterization of the dose-response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower GP MDI dose range to determine an optimal dose for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Abstract Background Long-acting muscarinic antagonist/long-acting β 2 -agonist combinations are recommended for patients whose chronic obstructive pulmonary disease (COPD) is not managed with monotherapy. We assessed the efficacy and safety of glycopyrrolate (GP)/formoterol fumarate (FF) fixed-dose combination delivered via a Co-Suspension™ Delivery Technology-based metered dose inhaler (MDI) (GFF MDI). Methods This was a Phase IIb randomized, multicenter, placebo-controlled, double-blind, chronic-dosing (7 days), crossover study in patients with moderate-to-very severe COPD (NCT01085045). Treatments included GFF MDI twice daily (BID) (GP/FF 72/9.6 μg or 36/9.6 μg), GP MDI 36 μg BID, FF MDI 7.2 and 9.6 μg BID, placebo MDI, and open-label formoterol dry powder inhaler (FF DPI) 12 μg BID or tiotropium DPI 18 μg once daily. The primary endpoint was forced expiratory volume in 1 s area under the curve from 0 to 12 h (FEV 1 AUC 0–12 ) on Day 7 relative to baseline FEV 1 . Secondary endpoints included pharmacokinetics and safety. Results GFF MDI 72/9.6 μg or 36/9.6 μg led to statistically significant improvements in FEV 1 AUC 0–12 after 7 days’ treatment versus monocomponent MDIs, placebo MDI, tiotropium, or FF DPI (p ≤ 0.0002). GFF MDI 36/9.6 μg was non-inferior to GFF MDI 72/9.6 μg and monocomponent MDIs were non-inferior to open-label comparators. Pharmacokinetic results showed glycopyrrolate and formoterol exposure were decreased following administration via fixed-dose combination versus monocomponent MDIs; however, this was not clinically meaningful. GFF MDI was well tolerated. Conclusions GFF MDI 72/9.6 μg and 36/9.6 μg BID improve lung function and are well tolerated in patients with moderate-to-very severe COPD. Trial registration ClinicalTrials.gov NCT01085045. Registered 9 March 2010

SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes

Evidence suggests an association between severe acute respiratory syndrome-cornavirus-2 (SARS-CoV-2) infection and the occurrence of new-onset diabetes. We examined pancreatic expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), the cell entry factors for SARS-CoV-2, using publicly available single-cell RNA sequencing data sets, and pancreatic tissue from control male and female nonhuman primates (NHPs) and humans. We also examined SARS-CoV-2 immunolocalization in pancreatic cells of SARS-CoV-2-infected NHPs and patients who had died from coronavirus disease 2019 (COVID-19). We report expression of ACE2 in pancreatic islet, ductal, and endothelial cells in NHPs and humans. In pancreata from SARS-CoV-2-infected NHPs and COVID-19 patients, SARS-CoV-2 infected ductal, endothelial, and islet cells. These pancreata also exhibited generalized fibrosis associated with multiple vascular thrombi. Two out of 8 NHPs developed new-onset diabetes following SARS-CoV-2 infection. Two out of 5 COVID-19 patients exhibited new-onset diabetes at admission. These results suggest that SARS-CoV-2 infection of the pancreas may promote acute and especially chronic pancreatic dysfunction that could potentially lead to new-onset diabetes